Senores Pharmaceuticals Ltd (SENORES) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed FY27 guidance for 30-40% revenue and 50-60% PAT growth, citing a stronger H2 from new launches and venture commercialization.
- The US ventures Amerigen and Zoraya are expected to begin commercial operations in Q3 FY27, with Amerigen launching over 10 products within two quarters.
- The company plans to expand its key Apnar facility to four commercial lines by March 2027, increasing production capacity to 1.2 billion units annually.
Performance Overview
- Achieved the highest ever quarterly revenue and EBITDA, marking the ninth consecutive quarter of surpassing stated guidance.
- Regulated markets business demonstrated strong growth of 28% YoY in Q2, driven by an expanding ANDA portfolio.
- The ANDA portfolio nearly doubled in a year, reaching 64 approved ANDAs by September 2026.
- Profitability improved with EBITDA and PAT growing faster than revenue, showcasing operating leverage.
- Significant investments were made in R&D for complex products, capacity expansion, and digitization with SAP HANA.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.